Press releases
Access archived Guidant press releases
Access archived BTG press releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Nov 30, 2012
The first patient has been enrolled in the Boston Scientific Corporation (NYSE: BSX) EVOLVE II clinical trial, which is designed to further assess the...
-
Nov 20, 2012Devices Projected to Have up to Twice the Longevity of Comparable Products
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for increased longevity projections for the INCEPTA™, ENERGEN™, PUNCTUA™,...
-
Nov 8, 2012Company to Consolidate Natick, Mass. Headquarters into Existing Marlborough Site; Facility Expansion to Create Collaborative Campus Setting; Consolidation Expected to be Completed by Mid-Summer 2014
Natick, Mass. (November 8, 2012) – Boston Scientific Corporation (NYSE:BSX) announces it will consolidate its Natick, Mass. global headquarters into its Marlborough, Mass. location, where a new...
-
Nov 8, 2012Company to Strengthen Hypertension Program with Acquisition of Renal Denervation Technology
Boston Scientific Corporation (NYSE: BSX) is extending its reach into the strategically critical renal denervation market by signing a definitive...
-
Nov 6, 2012MADIT-RIT Clinical Trial Study Results Published Today in the New England Journal of Medicine
Boston Scientific Corporation (NYSE: BSX) and the University of Rochester Medical Center presented positive results from the Multicenter Automatic...
-
Nov 1, 2012Appointment Completes Company's CEO Transition Plan; Mahoney Replaces Interim CEO William H. (Hank) Kucheman
In an expected move that follows a previously announced leadership transition period, Boston Scientific Corporation (NYSE: BSX) today named Michael F....
-
Oct 31, 2012This Innovative Bioabsorbable Coating is the First to Complete Absorption Shortly after Drug Elution Ends at Three Months
Boston Scientific Corporation (NYSE: BSX) received CE Mark approval for the SYNERGY™ Everolimus-Eluting Platinum Chromium Coronary Stent System...
-
Oct 24, 2012
Boston Scientific Corporation (NYSE:BSX) has received approval to update the directions for use (DFU) labeling for PROMUS Element™ and PROMUS...
-
Oct 23, 2012PLATINUM Long Lesion Clinical Results Presented at TCT 2012 Show No Heart Attack or Stent Thrombosis at Two-Year Follow-Up
Boston Scientific Corporation (NYSE: BSX) reports clinical endpoint data from the PLATINUM Long Lesion trial, demonstrating positive outcomes for the...
-
Oct 23, 2012Twelve-Month Data Presented at TCT 2012 Support Safety and Efficacy of Epic Stent in Iliac Stenting
Boston Scientific Corporation (NYSE: BSX) reports twelve-month clinical endpoint data from the ORION trial, which demonstrated robust safety and...